In a secondary analysis of the STEP TEENS trial, semaglutide proved to be a significant treatment for adolescent obesity, with 45% of the semaglutide-treated participants losing enough weight to drop below the obesity cutoff, and 74% moved down at least one BMI category after 68 weeks.
Nearly Half of Adolescents Using Semaglutide in Trial Dropped Below the Clinical Cut-Off for Obesity
A secondary analysis of the STEP TEENS trial, published in the Obesity journal and presented at the European Congress on Obesity 2023, has found that semaglutide is effective in treating obesity in adolescents. Nearly half (45%) of the participants treated with semaglutide managed to lose enough weight to be classified below the obesity cutoff, and about three-quarters (74%) experienced a drop in at least one body mass index (BMI) category. The trial initially involved 201 adolescents with high BMIs, who were randomized into groups receiving either a placebo or weekly semaglutide injections alongside lifestyle counseling for 68 weeks. After this period, the semaglutide group demonstrated significant improvements in BMI categories compared to the placebo group, with a marked reduction in those with severe obesity.
A new secondary analysis of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) and published in the journal Obesity shows that almost half (45%) of the adolescents assigned to semaglutide in the trial managed to lose enough weight to drop below the clinical cutoff for obesity.
The study, led by Aaron S. Kelly, PhD, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, Minneapolis, and colleagues, also showed almost three quarters (74%) moved down by at least one weight category.
The full STEP TEENS trial, published in 2022 in the New England Journal of Medicine (NEJM), showed the efficacy of semaglutide in helping adolescents lose weight. In this secondary analysis of the STEP TEENS trial, the authors examined the effect of semaglutide treatment on improvement in body mass index (BMI) categories.
On June 4, 2021, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
Adolescents aged 12 to under 18 years with BMI in the highest 5% were included in this analysis. Participants were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg (n=134) or placebo (n=67) for 68 weeks; both groups received matching lifestyle counseling. The proportion of participants who achieved an improvement in BMI category from baseline to week 68 was assessed using on-treatment data.
BMI categories, based on Centers for Disease Control and Prevention BMI charts, were: normal weight (BMI ≥5th to <85th percentile); overweight (BMI ≥85th to <95th percentile); and obesity class I (OCI; BMI ≥95th percentile). Severe obesity class II (OCII) and class III (OCIII) are based on a percentage above the 95th percentile cutoff for obesity – OCII is defined as ≥20% above this cutoff and OCIII is defined as ≥40% above this cutoff.
Of 201 adolescents randomized, 62 (31%), 69 (34%) and 69 (34%) were in OCIII, OCII and OCI, respectively; only one participant (0.5%) had overweight and was excluded from this secondary analysis. At randomization, mean body weight was 107.5 kg and mean BMI was 37.0 kg/m2 (OCII).
At week 68, 74% of participants on semaglutide had an improvement of one or more BMI categories versus 19% on placebo. An improvement of ≥2 BMI categories occurred in 45% of participants treated with semaglutide versus 3% with placebo. Overall, treatment with semaglutide reduced the proportion of participants with the most severe degree of obesity (OCIII) from 37% to 14% after 68 weeks.
By week 68, a total of 45% participants in the semaglutide arm experienced a reduction in BMI below the clinical cutoff point for obesity (i.e., reached normal weight or overweight) versus 12% of participants in the placebo arm.
The authors concluded, “Once-weekly semaglutide was associated with clinically meaningful improvements in BMI categories versus PBO across all BMI classes in adolescents with obesity.”
“These results underscore the high degree of clinical effectiveness of semaglutide in adolescents with obesity,” said Kelly. “In a practical sense, we see that semaglutide reduced weight to a level below what is defined as clinical obesity in nearly 50% of the teens in our trial, which is historically unprecedented with treatments other than bariatric surgery.”
Kelly presented this study at ECO 2023 on Wednesday, May 17, 2023.
References:
“Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg” by Aaron S. Kelly, Silva Arslanian, Dan Hesse, Aske Thorn Iversen, Antje Körner, Signe Schmidt, Rasmus Sørrig, Daniel Weghuber and Ania M. Jastreboff, 17 May 2023, Obesity.
DOI: 10.1002/oby.23808
“Once-Weekly Semaglutide in Adolescents with Obesity” by Daniel Weghuber, M.D., Timothy Barrett, Ph.D., Margarita Barrientos-Pérez, M.D., Inge Gies, Ph.D., Dan Hesse, Ph.D., Ole K. Jeppesen, M.Sc., Aaron S. Kelly, Ph.D., Lucy D. Mastrandrea, M.D., Rasmus Sørrig, Ph.D., and Silva Arslanian, M.D. for the STEP TEENS Investigators, 15 December 2022, The New England Journal of Medicine.
DOI: 10.1056/NEJMoa2208601
Discussion about this post